Upregulation of MAPK pathway is associated with survival in castrate-resistant prostate cancer

British Journal of Cancer

Volumn 104, Issue 12, 2011, Pages 1920-1928

  Mukherjee, R ^a,b   McGuinness, D H ^a   McCall, P ^a   Underwood, M A ^b   Seywright, M ^b   Orange, C ^b   Edwards, J ^a  

^a UNIVERSITY OF GLASGOW   (United Kingdom)

^b Glasgow Royal Inf Irmary ^*  (United Kingdom)

Author keywords

AP 1; castrate resistant prostate cancer; Her2; MAP kinase pathway; prostate cancer; Raf

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; MITOGEN ACTIVATED PROTEIN KINASE; RAF PROTEIN; TRANSCRIPTION FACTOR AP 1; TYROSINE KINASE RECEPTOR;

AGED; ARTICLE; CANCER RELAPSE; CANCER SURVIVAL; CARCINOGENESIS; CASTRATION RESISTANT PROSTATE CANCER; CONTROLLED STUDY; CORRELATION COEFFICIENT; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROTEIN EXPRESSION; STATISTICAL SIGNIFICANCE; UPREGULATION;

AGED; HUMANS; MALE; MAP KINASE SIGNALING SYSTEM; MITOGEN-ACTIVATED PROTEIN KINASES; ORCHIECTOMY; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; PROTO-ONCOGENE PROTEINS C-RAF; RECEPTOR, ERBB-2;

EID: 79958098599     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/bjc.2011.163     Document Type: Article

References (42)

1. Abreu-Martin MT, Chari A, Palladino AA, Craft NA, Sawyers CL (1999) Mitogen-activated protein kinase kinase kinase 1 activates androgen receptor-dependent transcription and apoptosis in prostate cancer. Mol Cell Biol 19: 5143-5154 (Pubitemid 29289552)
2. Alessandrini A, Chiaur DS, Pagano M (1997) Regulation of the cyclin-dependent kinase inhibitor p27 by degradation and phosphorylation. Leukemia 11: 342-345 (Pubitemid 27120981)
3. Bakin RE, Gioeli D, Sikes RA, Bissonette EA, Weber MJ (2003) Constitutive activation of the Ras/mitogen-activated protein kinase signaling pathway promotes androgen hypersensitivity in LNCaP prostate cancer cells. Cancer Res 63: 1981-1989 (Pubitemid 36460867)
4. Bartlett JM, Brawley D, Grigor K, Munro AF, Dunne B, Edwards J (2005) Type I receptor tyrosine kinases are associated with hormone escape in prostate cancer. J Pathol 205: 522-529 (Pubitemid 40361342)
5. Beemsterboer PM, de Koning HJ, Birnie E, van der Maas PJ, Schroder FH (1999) Advanced prostate cancer: course, care, and cost implications. Prostate 40: 97-104 (Pubitemid 29304700)
6. Bonaccorsi L, Muratori M, Carloni V, Zecchi S, Formigli L, Forti G, Baldi E (2003) Androgen receptor and prostate cancer invasion. Int J Androl 26: 21-25 (Pubitemid 36110851)
7. Bradham C, McClay DR (2006) p38 MAPK in development and cancer. Cell Cycle 5: 824-828 (Pubitemid 44145574)
8. CancerResearchUK (2010) http://info.cancerresearchuk.org/cancerstats/ incidence/
9. Cuadrado A, Nebreda AR (2010) Mechanisms and functions of p38 MAPK signalling. Biochem J 429: 403-417
10. Culig Z, Klocker H, Bartsch G, Hobisch A (2002) Androgen receptors in prostate cancer. Endocr Relat Cancer 9: 155-170 (Pubitemid 35175976)
11. Dasgupta P, Sun J, Wang S, Fusaro G, Betts V, Padmanabhan J, Sebti SM, Chellappan SP (2004) Disruption of the Rb-Raf-1 interaction inhibits tumor growth and angiogenesis. Mol Cell Biol 24: 9527-9541 (Pubitemid 39391689)
12. Debes JD, Tindall DJ (2004) Mechanisms of androgen-refractory prostate cancer. N Engl J Med 351: 1488-1490 (Pubitemid 39315314)
13. Dhillon AS, Meikle S, Peyssonnaux C, Grindlay J, Kaiser C, Steen H, Shaw PE, Mischak H, Eychene A, Kolch W (2003) A Raf-1 mutant that dissociates MEK/extracellular signal-regulated kinase activation from malignant transformation and differentiation but not proliferation. Mol Cell Biol 23: 1983-1993 (Pubitemid 36278810)
14. Dorkin TJ, Neal DE (1997) Basic science aspects of prostate cancer. Semin Cancer Biol 8: 21-27 (Pubitemid 27417426)
15. Edwards J, Bartlett JM (2005) The androgen receptor and signal-transduction pathways in hormone-refractory prostate cancer. Part 1: modifications to the androgen receptor. BJU Int 95: 1320-1326
16. Edwards J, Krishna NS, Grigor KM, Bartlett JM (2003a) Androgen receptor gene amplification and protein expression in hormone refractory prostate cancer. Br J Cancer 89: 552-556 (Pubitemid 37026442)
17. Edwards J, Krishna NS, Mukherjee R, Bartlett JM (2004) The role of c-Jun and c-Fos expression in androgen-independent prostate cancer. J Pathol 204: 153-158 (Pubitemid 39335288)
18. Edwards J, Krishna NS, Mukherjee R, Watters AD, Underwood MA, Bartlett JM (2001) Amplification of the androgen receptor may not explain the development of androgen-independent prostate cancer. BJU Int 88: 633-637 (Pubitemid 34293810)
19. Edwards J, Krishna NS, Witton CJ, Bartlett JM (2003b) Gene amplifications associated with the development of hormone-resistant prostate cancer. Clin Cancer Res 9: 5271-5281 (Pubitemid 37413579)
20. Edwards J, Traynor P, Munro AF, Pirret CF, Dunne B, Bartlett JM (2006) The role of HER1-HER4 and EGFRvIII in hormone-refractory prostate cancer. Clin Cancer Res 12: 123-130 (Pubitemid 43166185)
21. Franco OE, Onishi T, Yamakawa K, Arima K, Yanagawa M, Sugimura Y, Kawamura J (2003) Mitogen-activated protein kinase pathway is involved in androgen-independent PSA gene expression in LNCaP cells. Prostate 56: 319-325 (Pubitemid 36988753)
22. Fu Z, Smith PC, Zhang L, Rubin MA, Dunn RL, Yao Z, Keller ET (2003) Effects of raf kinase inhibitor protein expression on suppression of prostate cancer metastasis. J Natl Cancer Inst 95: 878-889 (Pubitemid 36833879)
23. Galea MH, Blamey RW, Elston CE, Ellis IO (1992) The Nottingham Prognostic Index in primary breast cancer. Breast Cancer Res Treat 22: 207-219
24. Gao X, Porter AT, Grignon DJ, Pontes JE, Honn KV (1997) Diagnostic and prognostic markers for human prostate cancer. Prostate 31: 264-281 (Pubitemid 27247318)
25. Gioeli D, Mandell JW, Petroni GR, Frierson Jr HF, Weber MJ (1999) Activation of mitogen-activated protein kinase associated with prostate cancer progression. Cancer Res 59: 279-284 (Pubitemid 29048852)
26. Huggins C, Hodges CV (2002) Studies on prostatic cancer: I. The effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate. 1941. J Urol 168: 9-12
27. Jilaveanu LB, Zito CR, Aziz SA, Conrad PJ, Schmitz JC, Sznol M, Camp RL, Rimm DL, Kluger HM (2009) C-Raf is associated with disease progression and cell proliferation in a subset of melanomas. Clin Cancer Res 15: 5704-5713
28. Karreth FA, DeNicola GM, Winter SP, Tuveson DA (2009) C-Raf inhibits MAPK activation and transformation by B-Raf(V600E). Mol Cell 36: 477-486
29. Khleif SN, Abrams SI, Hamilton JM, Bergmann-Leitner E, Chen A, Bastian A, Bernstein S, Chung Y, Allegra CJ, Schlom J (1999) A phase I vaccine trial with peptides reflecting ras oncogene mutations of solid tumors. J Immunother 22: 155-165 (Pubitemid 29135900)
30. Linja MJ, Savinainen KJ, Saramaki OR, Tammela TL, Vessella RL, Visakorpi T (2001) Amplification and overexpression of androgen receptor gene in hormone-refractory prostate cancer. Cancer Res 61: 3550-3555 (Pubitemid 32694958)
31. Mukherjee R, Bartlett JM, Krishna NS, Underwood MA, Edwards J (2005) Raf-1 expression may influence progression to androgen insensitive prostate cancer. Prostate 64: 101-107 (Pubitemid 40734744)
32. Roskoski Jr R (2010) RAF protein-serine/threonine kinases: structure and regulation. Biochem Biophys Res Commun 399: 313-317
33. Sadar MD, Hussain M, Bruchovsky N (1999) Prostate cancer: molecular biology of early progression to androgen independence. Endocr Relat Cancer 6: 487-502 (Pubitemid 30048459)
34. Sato N, Sadar MD, Bruchovsky N, Saatcioglu F, Rennie PS, Sato S, Lange PH, Gleave ME (1997) Androgenic induction of prostate-specific antigen gene is repressed by protein-protein interaction between the androgen receptor and AP-1/c-Jun in the human prostate cancer cell line LNCaP. J Biol Chem 272: 17485-17494 (Pubitemid 27311181)
35. Sciarra A, Casale P, Colella D, Di Chiro C, Di Silverio F (1999) Hormone-refractory prostate cancer? Anti-androgen withdrawal and intermittent hormone therapy. Scand J Urol Nephrol 33: 211-216 (Pubitemid 29439084)
36. Stamey TA, Yang N, Hay AR, McNeal JE, Freiha FS, Redwine E (1987) Prostate-specific antigen as a serum marker for adenocarcinoma of the prostate. N Engl J Med 317: 909-916 (Pubitemid 17147932)
37. Ueda T, Bruchovsky N, Sadar MD (2002) Activation of the androgen receptor N-terminal domain by interleukin-6 via MAPK and STAT3 signal transduction pathways. J Biol Chem 277: 7076-7085 (Pubitemid 34959964)
38. Weinstein-Oppenheimer CR, Blalock WL, Steelman LS, Chang F, McCubrey JA (2000) The Raf signal transduction cascade as a target for chemotherapeutic intervention in growth factor-responsive tumors. Pharmacol Ther 88: 229-279 (Pubitemid 32406054)
39. Wirth MP, See WA, McLeod DG, Iversen P, Morris T, Carroll K (2004) Bicalutamide 150 mg in addition to standard care in patients with localized or locally advanced prostate cancer: results from the second analysis of the early prostate cancer program at median followup of 5.4 years. J Urol 172: 1865-1870 (Pubitemid 39363075)
40. Wise SC, Burmeister LA, Zhou XF, Bubulya A, Oberfield JL, Birrer MJ, Shemshedini L (1998) Identification of domains of c-Jun mediating androgen receptor transactivation. Oncogene 16: 2001-2009 (Pubitemid 28200612)
41. Yeh S, Lin HK, Kang HY, Thin TH, Lin MF, Chang C (1999) From HER2/Neu signal cascade to androgen receptor and its coactivators: a novel pathway by induction of androgen target genes through MAP kinase in prostate cancer cells. Proc Natl Acad Sci USA 96: 5458-5463 (Pubitemid 29234639)
42. Zelivianski S, Spellman M, Kellerman M, Kakitelashvilli V, Zhou XW, Lugo E, Lee MS, Taylor R, Davis TL, Hauke R, Lin MF (2003) ERK inhibitor PD98059 enhances docetaxel-induced apoptosis of androgen-independent human prostate cancer cells. Int J Cancer 107: 478-485 (Pubitemid 37266470)